PMID- 36474670
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221207
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 9
DP  - 2022
TI  - Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus 
      Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine 
      Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
PG  - 1217-1228
LID - 10.2147/JHC.S386672 [doi]
AB  - OBJECTIVE: This study aimed to evaluate the effectiveness and safety of 
      transarterial chemoembolization (TACE) in combination with immune checkpoint 
      inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) (TACE+IT) versus ICIs 
      plus TKIs (IT) for advanced hepatocellular carcinoma (HCC). MATERIALS AND 
      METHODS: Data of consecutive advanced HCC patients receiving TACE+IT or IT 
      between January 2019 and December 2021 were included and were retrospectively 
      analyzed. Propensity score matching (PSM) was performed to reduce bias due to 
      confounding variables. The primary outcome of the study was overall survival 
      (OS). The secondary outcomes were progression-free survival (PFS), objective 
      response rate (ORR), disease control rate (DCR), and adverse events (AEs), 
      respectively. RESULTS: Sixty-four patients were enrolled in the study, among 
      which 24 and 40 received TACE+IT and IT, respectively. The PSM cohort included 24 
      patients receiving TACE+IT (TACE+IT group) and 24 patients receiving IT (IT 
      group) alone. During a median follow-up of 23 months, patients in TACE+IT group 
      had significantly longer OS (median, 17.3 vs 11.8 months, P = 0.023), better ORR 
      (41.7% vs 12.5%, P = 0.023) and DCR (79.2% vs 50.0%, P = 0.035) than those in the 
      IT group, whereas a non-significant trend in PFS (median, 7.4 vs 6.7 months, P = 
      0.23) was observed. According to multivariable cox regression analysis, it was 
      found that treatment modality was the only independent risk factor for OS (HR = 
      0.404, 95% CI = 0.179-0.911, P < 0.05). There were no remarkable differences in 
      AEs associated with ICIs and TKIs between the two groups, with the exception of 
      gastrointestinal reaction. CONCLUSION: TACE combined with ICIs plus TKIs 
      significantly improved OS, ORR, and DCR and showed a relatively longer PFS trend 
      over ICIs combined with TKIs for advanced HCC.
CI  - (c) 2022 Huang et al.
FAU - Huang, Jin-Tao
AU  - Huang JT
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Zhong, Bin-Yan
AU  - Zhong BY
AUID- ORCID: 0000-0001-9716-1211
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Jiang, Nan
AU  - Jiang N
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Li, Wan-Ci
AU  - Li WC
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Yin, Yu
AU  - Yin Y
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Yang, Jun
AU  - Yang J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Shen, Jian
AU  - Shen J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Wang, Wan-Sheng
AU  - Wang WS
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Zhu, Xiao-Li
AU  - Zhu XL
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20221130
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC9719708
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - transarterial chemoembolization
OT  - tyrosine kinase inhibitors
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/12/08 06:00
MHDA- 2022/12/08 06:01
PMCR- 2022/11/30
CRDT- 2022/12/07 02:07
PHST- 2022/08/25 00:00 [received]
PHST- 2022/11/22 00:00 [accepted]
PHST- 2022/12/07 02:07 [entrez]
PHST- 2022/12/08 06:00 [pubmed]
PHST- 2022/12/08 06:01 [medline]
PHST- 2022/11/30 00:00 [pmc-release]
AID - 386672 [pii]
AID - 10.2147/JHC.S386672 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2022 Nov 30;9:1217-1228. doi: 10.2147/JHC.S386672. 
      eCollection 2022.